A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease

American Journal of Gastroenterology

Volumn 92, Issue 2, 1997, Pages 279-282

  Riley, Thomas R ^a,b   Schoen, Robert E ^a   Lee, Randall G ^a   Rakela, Jorge ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; TACROLIMUS;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT ATRESIA; CLINICAL ARTICLE; CROHN DISEASE; ENTERITIS; FEMALE; GRAFT REJECTION; HEPATITIS NON A NON B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; OBSTRUCTIVE UROPATHY; POSTOPERATIVE COMPLICATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TREATMENT INDICATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 0031046564     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Strober W, James SP. The immunologic basis of inflammatory bowel disease. J Clin Immunol 1986;6:415-32.
2. Macdonald TT, Murch SH. Aetiology and pathogenesis of chronic inflammatory bowel disease. Ballieres Clin Gastroenterol 1994;8:1-34.
3. Mourn B, Vatn MH, Ekbom A, et al. Incidence of inflammatory bowel disease in southeastern Norway: Evaluation of methods after 1 year of registration. Digestion 1995;56:377-81.
4. Whelan G. Epidemiology of inflammatory bowel disease. Med Clin North Am 1990;74:1-12.
5. Passfall J, Distler A, Riecken EO, et al. Development of ulcerative colitis under the immunosuppressive effect of cyclosporine. Clin Invest 1992;70:611-3.
6. Larusso NF, Wiesner RH, Ludwig J, et al. Primary sclerosing cholangitis. N Engl J Med 1984;310:899-903.
7. Shaked A, Colonna JO, Goldstein L, et al. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992;215:598-605.
8. Gavaler JS, Delemos B, Belle SH, et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation. Dig Dis Sci 1991;36:321-8.
9. Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholansitis patients. Transplant Proc 1993; 25:1122-3.
10. Lockhart-Mummery HE, Morson BC. Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut 1960;1:87-105.
11. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334: 841-8.
12. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-31.
13. Brynskov J, Nielson OH, Ahnfelt-Ronne I, et al. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review. Dig Dis 1994;12:290-304.
14. Senju M, Hulstaert F, Lowder J, et al. Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease. Gut 1991;32:779-83.
15. Hoang P, Senju M, Lowes JR, et al. Phenotypic characterization of isolated intraepithelial lymphocytes in patients with ulcerative colitis and normal controls. Dig Dis Sci 1992;37:1725-8.
16. Neissner M, Volk BA. Phenotypic and immunoregulatory analysis of intestinal T-cells in patients with inflammatory bowel disease: Evaluation of an in vitro model. Eur J Clin Invest 1995;25:155-64.
17. James SP. Remission of Crohn's disease after human immunodefiecency virus infection. Gastroenterology 1988;95:1667-9.
18. Sparono JA, Brandt LJ, Dutcher JP, et al. Symptomatic exacerbation of Crohn's disease after treatment with high-dose interleukin-2. Ann Intern Med 1993;118:617-8.